Claims for Patent: 8,530,454

Summary for Patent: 8,530,454

Title:	Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of psoriasis
Abstract:	The present invention relates to the use of a 2,5-dihydroxybenzene derivative of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the treatment and/or prophylaxis of, inter alia, psoriasis.
Inventor(s):	Cuevas Sanchez; Pedro (Madred, ES), Gimenez Gallego; Guillermo (Madrid, ES), Saenz de Tejada Gorman; Inigo (Madrid, ES), Angulo Frutos; Javier (Madrid, ES), Valverde Lopez; Serafin (Madrid, ES), Romero Garrido; Atonio (Madrid, ES), Lozano Puerto; Rosa Maria (Madrid, ES)
Assignee:	Amderma Pharmaceuticals, LLC (Bridgewater, NJ)
Application Number:	13/166,569
Patent Claims:	1. A method for the treatment of psoriasis, comprising administering to a subject having psoriasis, an effective amount of a 2,5-dihydroxybenzene derivative represented by Formula (I) or a pharmaceutically acceptable salt, solvate, or isomer thereof, wherein the compound of Formula (I) is: ##STR00007## wherein: R.sub.1 is --(CH.sub.2).sub.aY or --CH.dbd.CH--(CH.sub.2).sub.pZ; Y is --SO.sub.3H, --SO.sub.3R.sub.3, --PO.sub.3H, --PO.sub.3.sup.-.X.sup.+, or --PO.sub.3R.sub.3, wherein when Y is --SO.sub.3H, --SO.sub.3.sup.-.X.sup.+ or --SO.sub.3R.sub.3, then R.sub.9 and R.sub.9' are independently selected from --OH and --OR.sub.2, wherein at least one of R.sub.9 and R.sub.9' is a substituted or unsubstituted alkylsulfonyloxy group, a substituted or unsubstituted arylsulfonyloxy group, a substituted or unsubstituted alkylcarbonyloxy group or a substituted or unsubstituted arylcarbonyloxy group; Z is --SO.sub.3H, --SO.sub.3.sup.-.X.sup.+, --SO.sub.3R.sub.3, --PO.sub.3H, --PO.sub.3.sup.-.X.sup.+, --PO.sub.3R.sub.3, --CO.sub.2H, --CO.sub.2.sup.-.X.sup.+ or --CO.sub.2R.sub.3; X.sup.+ is an organic cation or an inorganic cation, such that the general charge of the compound is neutral; R.sub.9 and R.sub.9' are independently selected from --OH and --OR.sub.2, wherein when R.sub.9 and R.sub.9' are both --OR.sub.2, then said R.sub.9 and R.sub.9' can be the same or different; R.sub.2 is a substituted or unsubstituted alkyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted alkylsulfonyl group, a substituted or unsubstituted arylsulfonyl group, a substituted or unsubstituted alkylcarbonyl group or a substituted or unsubstituted arylcarbonyl group; R.sub.3 is a substituted or unsubstituted alkyl group or a substituted or unsubstituted aryl group; a is a number selected from 0, 1, 2, 3, 4, 5 and 6; and p is an integer selected from 0, 1, 2, 3, 4, 5 and 6. 2. The method of claim 1, wherein R.sub.1 is --(CH.sub.2).sub.aY or --CH.dbd.CH--(CH.sub.2).sub.pY. 3. The method of claim 2, wherein Y is selected from --SO.sub.3H, --SO.sub.3.sup.-.X.sup.+, --SO.sub.3R.sub.3. 4. The method of claim 2, wherein R.sub.3 is selected from methyl and ethyl. 5. The method of claim 1, wherein R.sub.9 and R.sub.9' are, independently, a substituted or unsubstituted alkylsulfonyloxy group, a substituted or unsubstituted arylsulfonyloxy group, a substituted or unsubstituted alkylcarbonyloxy group or a substituted or unsubstituted arylcarbonyloxy group. 6. The method of claim 1, wherein R.sub.2 is selected from methylcarbonyl, phenylsulfonyl, 4-methylphenylsulfonyl, benzylsulfonyl, benzyl and phenyl. 7. The method of claim 1, wherein the compound of Formula (I) is selected from the group consisting of: 5-hydroxy-2-{[(4-methylphenyl)sulfonyl]oxy}benzenesulfonic acid; 2-hydroxy-5-{[(4-methylphenyl)sulfonyl]oxy}benzenesulfonic acid; 2,5-bis{[(4-methylphenyl)sulfonyl]oxy}benzenesulfonic acid; 2-(acetyloxy)-5-hydroxybenzenesulfonic acid; 5-(acetyloxy)-2-hydroxybenzenesulfonic acid; 2,5-bis(acetyloxy)benzenesulfonic acid; 5-hydroxy-2-{[(4-methylphenyl)sulfonyl]oxy}benzenehomosulfonic acid; 2-hydroxy-5-{[(4-methylphenyl)sulfonyl]oxy}benzenehomosulfonic acid; 2,5-bis{[(4-methylphenyl)sulfonyl]oxy}benzenehomosulfonic acid; 2-(acetyloxy)-5-hydroxybenzenehomosulfonic acid; 5-(acetyloxy)-2-hydroxybenzenehomosulfonic acid; 2,5-bis(acetyloxy)benzenehomosulfonic acid; 3-(2,5-dihydroxyphenyl)-2-propenoic acid (2,5-dihydroxycinnamic acid); 3-(5-hydroxy-2-{[(4-methylphenyl)sulfonyl]oxy}phenyl)-2-propenoic acid; 3-(2-hydroxy-5-{[(4-methylphenyl)sulfonyl]oxy}phenyl)-2-propenoic acid; 3-(2,5-bis{[(4-methylphenyl)sulfonyl]oxy}phenyl)-2-propenoic acid; 3-(2-(acetyloxy)-5-hydroxyphenyl)-2-propenoic acid; 3-(5-(acetyloxy)-2-hydroxyphenyl)-2-propenoic acid; 3-(2,5-bis(acetyloxy)phenyl)-2-propenoic acid; 3-(2-(benzyloxy)-5-hydroxyphenyl)-2-propenoic acid; 3-(5-(benzyloxy)-2-hydroxyphenyl)-2-propenoic acid; 3-(2,5-bis(benzyloxy)phenyl)-2-propenoic acid; and pharmaceutically acceptable salts, and solvates thereof. 8. The method of claim 7, wherein the compound of Formula (I) is selected from: 2-(acetyloxy)-5-hydroxybenzenesulfonic acid; 5-(acetyloxy)-2-hydroxybenzenesulfonic acid and 2,5-bis(acetyloxy)benzenesulfonic acid. 9. The method of claim 1, wherein the compound of Formula (I) is administered topically. 10. The method of claim 9, wherein the compound of Formula (I) is administered orally, buccally, transdermally, rectally, or otically. 11. The method of claim 1, further comprising administration of at least one additional therapeutic agent. 12. The method of claim 11, wherein the at least one additional therapeutic agent is selected from the group consisting of: a corticoid; a vitamin D analog; methrotrexate; ciclosporin; a fumarate; adalimunag; alefecept; afalizumab; etanercept; infliximab; a steroid, a retinoid; an antimicrobial compound; an antioxidant; an anti-inflammatory compound; salicylic acid; an endothelin antagonist; an immunomodulating agent; an angiogenesis inhibitor; a inhibitor of FGF, VEGF, HGF or EGF; an inhibitor of an EGF, FGF, VEGF, or HGF receptor; a tyrosine kinase inhibitor; a protein kinase C inhibitor; and a combination of two or more thereof. 13. The method of claim 1, further comprising at least one coadjuvant therapy selected from the group consisting of phototherapy and photochemotherapy. 14. The method of claim 9, wherein the compound is administered at least once per week. 15. The method of claim 14, wherein the compound is administered at least once per day. 16. The method of claim 15, wherein the compound is administered at least twice per day. 17. The method of claim 9, wherein the compound is present in a pharmaceutical composition in an amount of at least about 1% w/w. 18. The method of claim 17, wherein the compound is present in a pharmaceutical composition in an amount of at least about 2.5% w/w. 19. The method of claim 18, wherein the compound is present in a pharmaceutical composition in an amount of at least about 5% w/w. 20. The method of claim 19, wherein the compound is present in a pharmaceutical composition in an amount of at least about 10% w/w. 21. The method of claim 20, wherein the compound is present in a pharmaceutical composition in an amount of at least about 15% w/w. 22. The method of claim 10, wherein the compound is administered over a period of at least about one week. 23. The method of claim 22, wherein the compound is administered over a period of at least about four weeks.

Details for Patent 8,530,454

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	REMICADE	infliximab	For Injection	103772	08/24/1998		2026-08-16
Immunex Corporation	ENBREL	etanercept	For Injection	103795	11/02/1998		2026-08-16
Immunex Corporation	ENBREL	etanercept	For Injection	103795	05/27/1999		2026-08-16
Immunex Corporation	ENBREL	etanercept	Injection	103795	09/27/2004		2026-08-16
Immunex Corporation	ENBREL	etanercept	Injection	103795	02/01/2007		2026-08-16